Introduction
Childhood histiocytoses are a heterogeneous group of diseases characterized by evidence of tissue infiltration by benign, inflammatory cells, enriched with macrophages, also defined as 'histiocytes.' During the last two decades, advances in their understanding allowed to dissect diseases with very different pathogenesis and behavior. Original classification of histiocytosis, provided by the Histiocyte Society and recently updated, 1 defines three main groups: Langerhans cell histiocytosis (LCH, group I), hemophagocytic lymphohistiocytosis (HLH, group II) and other nonmalignant histiocytoses (group III). Groups I and II are by far the most important also according to their frequency, which comprised between 1:25 000 and 1:50 000 children per year. This means that childhood hisytiocytoses are rare diseases; yet, their clinical course, invariably fatal in selected subsets of patients, and the intriguing mechanisms of their pathogenesis brought these disorders under the focus of research of several groups worldwide.
LCH
Langerhans cell histiocytosis has an estimated incidence in the Nordic countries of 3.5-7 cases per million per year. 2 Dysregulated growth, activity and trafficking of LCs may result in LCH at any age. Clinical manifestations and course are highly variable, ranging from a solitary bone lesion-known for many years as 'eosinophilic granuloma'-to a disseminated, 'multisystem' disease with multiple-organ involvement and a severe, lymphoma-like, clinical course. The formerly known clinical patterns of 'Hand-Schuller-Christian' (proptosis þ cranial bone lesion þ diabetes insipidus) and 'Abt-Letterer-Siwe' diseases represent part of the continuous spectrum of the clinical manifestations of LCH. 3 The pathogenesis of LCH has been investigated for many years, as confirmed by its fortunate name of 'histiocytosis X,' but no final evidence has been achieved so far. 4, 5 A possible role for pathogens and especially for viral infection(s) has been repeatedly explored but never documented. Several lines of evidence, both in vivo and in vitro, document that the cytokine network is deranged in LCH; despite abundant tumor necrosis factor-a production, lesional DCs remain in an immature state and are induced to produce chemokines. 6 This may induce not only the retention of the lesional LC but also the recruitment and retention of other lesional cells. Evidence of clonality in involved tissue led some researchers to consider LCH as a neoplasm. Yet most specialists still consider that clonality may have alternative explanations, and LCH is not a cancer but rather a disorder in which deranged immune response may result from environmental exposure may be favored by congenital variants of some cytokine-chemokine function(s). 7 This concept might be in keeping with familial clustering of LCH in about 1% of patients. 8 Because of lack of information on pathogenesis, treatment of LCH has been traditionally aimed at controlling symptoms and preventing late sequelae, such as bone defects and endocrine defects, especially diabetes insipidus. Yet patients with LCH affecting more than one tissue/ organ ('multisystem disease,' MS-LCH), especially those with involvement of liver, lung, CNS and hematopoiesis, are to be considered as 'at risk' for organ failure and a lifethreatening condition; the 20% of patients with MS-LCH failing to achieve disease control after initial, 6-week standard chemotherapy (vinblastine and steroids) have a probability of survival in the range of 30%. 9, 10 In this setting, HSCT has been introduced as therapy for refractory/recurrent LCH since 1987. 11 In the beginning, its use has been hardly questioned since LCH was not a malignancy. Yet during the following years, several patients have been treated with either allo-(or even auto-) HSCT, and at present at least 27 such patients can be identified from the literature. Of the 16 who underwent transplant from a matched related donor (MRD), 11 (69%) were alive and free of disease after up to 12 years, while five died, two after reactivation (Table 1) . Of the five transplanted from a matched unrelated donor (MUD), three were alive while two died of early toxicity; all three patients transplanted from unrelated cord blood are reported to be alive; of the three with a mismatch related donor, only one was alive.
In the attempt to circumvent the likely inherent reporting bias, Egeler et al. performed an LCH survey from the International Bone Marrow Transplant Registry, European Bone Marrow Transplantation Registry and Japanese Registries (M Egeler, personal communication, 2007). They were able to rescue information on 22 patients with MS-LCH, 20 (91%) with hematopoietic and liver dysfunction, six with lung dysfunction and four with gastrointestinal involvement. Beyond such severe presenting features, all patients were also non-responders at front-line treatment, including at least steroid and vinblastine. At the time of transplant, at a median of 14 months (range, 4-37) from starting initial therapy, at a median age of 2 years, 16 (73%) showed progressive disease. The donors were identical siblings in nine (41%), related in eight (36%) and MUD in five (23%). The source for stem cells was BM in 12 (55%), peripheral blood in 6 (27%) and cord blood in 4 (18%). The conditioning regimen was as follows: BU/CY±other (VP16) in nine (41%); CY/TBI ± other (VP16/fludarabine) in eight (36%), TBI ± other (VP16/fludarabine/thiotepa) in three (14%), busulphan/fludarabine/ATG in one and CY/ fludarabine/ATG in one. GvHD prophylaxis was based on CSA/MTX þ steroids in 10 (45%), CSA þ steroids in nine (41%), tacrolimus þ MTX, T-cell depletion or none in one each. At a median follow-up of 4 years, 14 patients had died (64%) of either TRM (n ¼ 11, 50%) due to venoocclusive disease (VOD) (n ¼ 2) or infection (n ¼ 9), or with progressive disease (n ¼ 3, 31%); the remaining eight were alive, including four (27%), with no evidence of disease after 4, 25, 55 and 57 months (3 MRD and 1 MUD).
Overall, 10 of the 27 cases identified from the literature and 8 of the 22 from the registries were alive. One first learning from these data is that reactivation is not the main problem for patients with MS-LCH undergoing allo-HSCT, who instead suffer from a high rate of TRM.
To address this issue, in a recent report Steiner et al. summarized the experience of the Austrian, German and French groups in the use of allogeneic reduced-intensity conditioning regimen (RIC)-SCT for MS, refractory LCH in children. Their median age at diagnosis was 9.9 months, all had hematopoietic dysfunction and hepatosplenomegaly; remarkably, only four of them had bone involvement. The interval between front-line therapy and transplant was 350 days (124-637), indirectly confirming that RIC-HSCT was considered a difficult choice and possibly the last therapeutic option for these patients. Conditioning regimen included fludarabine in all patients, melphalan in eight, total lymphoid irradiation in six, TBI in two, antithymocyte globulin in five and Campath in four patients. RIC-HSCT was well tolerated with regard to common procedure-related complications. Two patients died at 50 and 69 days, respectively, while seven survived and showed no signs of disease activity (including one with nonengraftment and full autologous hematopoietic recovery) after median follow-up of 390 days post-SCT. 12 These data strongly suggested that RIC-SCT is feasible, and allows to markedly reduce TRM, thus representing a promising new salvage approach for refractory MS-LCH.
Familial HLH
Familial HLH (FHL) is a genetically heterogeneous disorder characterized by an hyperinflammatory syndrome with fever, hepatosplenomegaly, cytopenia and, less frequently, CNS involvement. 13 Frequent alterations include low levels of fibrinogen, high levels of ferritin, triglycerides and b-chain of soluble IL-2 receptor (sCD25).
14,15 Since symptoms may resemble those of leukemia or lymphoma, BM aspiration is usually performed early during the diagnostic work up, showing hemophagocytosis by activated macrophages, either at first or at repeated evaluations during the disease course. Differential diagnosis of HLH may be difficult. 16 For this purpose, diagnostic guidelines for HLH have been established by the Histiocyte Society. 17 In particular, demonstration of frequent association with common pathogens and evidence of impaired natural killer cytotoxic activity provided the rationale for considering HLH as a selective immune deficiency. 18 Starting from the original report by Farquhar in 1952, autosomal recessive inheritance was proposed. Linkage analysis led to the identification of an association between FHL and the genomic region 9q21.3-22 (FHL1, MIM 603552), where the gene responsible for the disease was not yet identified. A simultaneous report established a linkage with another region, 10q21-22, in which the perforin (PRF1) gene was identified as responsible for a wide proportion of cases of FHL (FHL2, MIM 603553). 19 In patients with FHL2, PRF1 mutations induce a complete or partial reduction of the synthesis of the perforin protein. As a result, the cytotoxic machinery of natural killer cells is markedly impaired. 19, 20 In 2003, a third locus, 17q25, was reported in linkage with FHL (FHL3, MIM 608898). 21 The product of the involved gene, the Munc13-4 protein, contributes to the priming of the secretory granules before they fuse into the plasma cell membrane. Mutations in this gene impair the delivery of the effector proteins, perforin and granzymes into the target cells, resulting in defective cellular cytotoxicity and a clinical picture overlapping that of FHL2. 22 Very recently, a fourth chromosomal region (6q24) has been reported in linkage with FHL in a subset of Kurdish patients (FHL4). 23 Mutations of the syntaxin11 gene, mapped in this region, are thought to alter intracellular vesicle trafficking of the phagocytic system.
The natural course of FHL is rapidly fatal within a few weeks in the majority of cases unless appropriate treatment, including corticosteroids, cyclosporine, etoposide and antithymocyte globulin, results in transient disease control. 24, 25 So far, only patients who underwent HSCT have been cured.
Several reports on the use of HSCT for FHL are available. 26, 27 Recently, the Histiocyte Society reported 86 children receiving front-line therapy according to the HLH-94 protocol 25 (etoposide, dexamethasone and cyclosporine), followed by allo-HSCT, between 1995 and 2000. The suggested conditioning regimen consisted of BU (16 mg/kg, days À9 to À6), CY (200 mg/kg, days À5 to À2) and etoposide (900 mg/m 2 , days À5 to À3). Their 3-year survival post-HSCT was 64 ± 10%; 71 ± 18% in the 24 patients with an MRD, 70±16% in the 33 with MUD, 50 ± 24% in the 16 with familial haploidentical donor and 54 ± 27% in the 13 with an MUD. The 43 children who had persistently active disease after 2 months of therapy had a 2.75 risk of failure vs those with inactive disease; mortality was predominantly transplant-related. 28 Cesaro et al. 29 have recently collected all cases of FHL enrolled in the Italian Associazione Italiana Ematologia Oncologia Pediatrica-Trapianto Midollo Osseo (AIEOP-TMO) registry. These 61 children, transplanted between 1989 and 2006, may partly overlap some of those included in the Histiocyte Society report. They had a median age at HSCT of 1.4 years (range, 0.27-15.9) with a median delay of 11 months from diagnosis. At a median follow-up of 1.5 years, 40 were alive, after having received a transplant from an MRD (n ¼ 20%), an MUD (n ¼ 57%) or a partially matched related donor; the most frequently used conditioning regimen was BU/CY, with or without VP16; anti-GVHD prophylaxis was based on cyclosporine and methotrexate in most cases. Of the 21 patients who died, 7 had VOD and 4 had infection by day 100. The probability of survival at 7 years was 56.9% (CI, 40-64). 30 Furthermore, 14 patients with FHL have been reported between 1998 and 2007, who underwent HSCT from an unrelated CB at an age ranging between 4 months and 65 years. Of them 11 survived for a median of 2 years.
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Conclusion, open problems and future perspectives Childhood histiocytoses represent a continuous challenge for the pediatric hematologist. FHL has now been recognized as a congenital immune deficiency and thus, since its natural course is often rapidly fatal, the main duty of the clinician is that of recognizing the disease, to establish currently available chemoimmunotherapy (best according to the trial HLH-2004). 24 It is important to remember that a similar picture may occur, especially in patients immunodepressed due to concurrent medications, in which a viral infection may cause the so-called 'virusassociated hemophagocytic syndrome', or 'secondary' HLH, which usually resolves with short-term therapy. 40, 41 In contrast, children with congenitally impaired cellular cytotoxicity will not be able to achieve long-term disease control unless they undergo HSCT. The safest way to make this differential diagnosis, bearing obvious therapeutic implications, is the identification of the underlying genetic defect, which in most cases occurs in the PRF1 gene (FHL-2) or in the Munc13-4 gene. In patients with a convincing clinical picture, evidence of persistently defective natural killer activity will be key, in the absence of familial recurrence or consanguinity, in considering them very likely affected by other still undefined genetic defects, which in Italy, for example, currently account for about 20% of such defects (unpublished data). Patients with X-linked lymphoproliferative disease (XLP), Griscelli or Chediak-Higashi diseases may also present with a similar clinical picture 16, 42 and respond to the same treatment including HSCT. Identification of the familial genetic marker will thus be pivotal not only for directing the therapeutic choice for the patient (Figure 1 ) but also for a correct genetic counselling and for prenatal diagnosis.
The scenario is less clear in LCH, where pathogenesis remains undefined. We consider LCH as a disease resulting from cytokine overproduction in a subject who is constitutionally unable to cope up with some environmental factor, likely a common (viral?) pathogen. Despite identification of standard therapy for MS-LCH, 20% of such cases remain at risk for treatment failure and a fatal clinical course. In these patients, allo-HSCT is at present a promising resource, especially if TRM may be reduced. To address this issue, the Histiocyte Society has launched a cooperative trial for use of RIC-SCT (Figure 2 ), which will hopefully enrol a number of patients allowing an unbiased evaluation of this novel approach. It is remarkable that several patients undergoing HSCT for refractory LCH show a slow recovery post transplant, suggesting that (innate?) immune derangement underlying MS-LCH is progressively controlled after recapitulation of the ontogeny of the immune system by allogeneic stem cell-derived precursors. This might be in keeping with recent evidence of association between LCH and cytokine gene polymorphism, chromosomal instability and 1% of familial clustering. 7, 8, 43, 44 The finding of persistent control of the disease in a few patents who underwent auto-HSCT or experienced autologous reconstitution remains to be clarified.
In conclusion, the role of HST in childhood histiocytoses is very important. Better understanding of the pathogenesis, in particular of genetic and immune function defects, will help to design more tailored and possibly less toxic regimens, reducing TRM and thus disclosing the way to final cure for the vast majority of these children or even a young adult.
